2 Information about atezolizumab

Marketing authorisation indication

2.1 Atezolizumab (Tecentriq, Roche) is indicated for 'adjuvant treatment following complete resection for adult patients with stage II to IIIA (7th edition of the UICC/AJCC-staging system) non-small-cell lung cancer (NSCLC) whose tumours have programmed cell death ligand-1 (PD‑L1) expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for atezolizumab.


2.3 The list price is £3,807.69 for a (1,200 mg) 20‑ml vial and £2,665.38 for a (840 mg) 14‑ml vial (excluding VAT; BNF online accessed July 2022).

2.4 The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)